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Therapeutic hypothermia, recently termed target temperature management (TTM), is the cornerstone of neuroprotective
strategy. Dating to the pioneer works of Fay, nearly 75 years of basic and clinical evidence support its therapeutic value.
Although hypothermia decreases the metabolic rate to restore the supply and demand of O2, it has other tissue-specific
effects, such as decreasing excitotoxicity, limiting inflammation, preventing ATP depletion, reducing free radical
production and also intracellular calcium overload to avoid apoptosis. Currently, mild hypothermia (33°C) has become a
standard in post-resuscitative care and perinatal asphyxia. However, evidence indicates that hypothermia could be useful
in neurologic injuries, such as stroke, subarachnoid hemorrhage and traumatic brain injury. In this review, we discuss the
basic and clinical evidence supporting the use of TTM in critical care for acute brain injury that extends beyond care after
cardiac arrest, such as for ischemic and hemorrhagic strokes, subarachnoid hemorrhage, and traumatic brain injury. We
review the historical perspectives of TTM, provide an overview of the techniques and protocols and the pathophysiologic
consequences of hypothermia. In addition, we include our experience of managing patients with acute brain injuries
treated using endovascular hypothermia.
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History
Therapeutic hypothermia for acute brain injury is the
intentional lowering of body temperature, with the ob-
jective of reducing tissue damage in the central nervous
system. Modern use of therapeutic hypothermia as a
neuroprotective strategy began in the 1940s with the
work of Fay [1], who reported the first series of patients
with traumatic brain injury who were treated using
hypothermia. Therapeutic hypothermia has become a
standardized method of care for improving neurological
results after cardiac arrest. This approach has been used
since the publication of two randomized studies with
positive outcomes, each of which used 33°C for 12 h to
24 h [2,3], respectively. Recently, a new randomized trial
revisited the question of target temperature and was un-
able to demonstrate any difference in mortality or in ad-
verse neurologic outcome in patients treated at 33°C
compared with those treated at 36°C [4]. Therapeutic* Correspondence: maxrovegno@uc.cl
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(http://creativecommons.org/publicdomain/zerohypothermia has been historically classified into: mild
(34.5–36.5°C), moderate (34.5–32°C), marked (28–32°C)
and profound hypothermia (<28°C) [5,6]. Actually, there is
a recommendation from five professional societies replaced
the term “therapeutic hypothermia” with the term “target
temperature management” (TTM) [7], which implies a
broad range for controlling body temperature; TTM can
also be applied to normothermia using a similar approach.
Overview of TTM
Techniques to induce and maintain hypothermia can be
divided into two types: external and internal cooling
methods. The first type includes the use of cooling blan-
kets, ice packs, alcohol baths, cold-water immersion,
cold-saline gastric lavage, and local cooling using helmet
devices. However, despite their non-invasive nature,
these methods have some disadvantages, such as com-
plex implementation, particularly in obese patients, high
nursing requirements, intense skin vasoconstriction - shiv-
ering, slow onset of the desired temperature and erratic
temperature maintenance [8]. Nevertherless, other surface
cooling devices allow heat exchange by external water cir-
culating, and using automatic feedback-control temperature
mechanism. Following cardiac, it arrest appears safe ands article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
Andresen et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2015) 23:42 Page 2 of 7effective in maintaining the target body temperature, with
lesser variation than traditional cooling blankets [9,10].
The second type includes internal cooling methods
that use central venous catheters to either infuse cool
saline or directly to reduce the blood temperature by
convection. A single study compared the cooling rates for
external and internal methods, showing rates of 0.9°C/h
and 4.8°C/h, respectively [11].
Induced hypothermia can be separated into three phases:
induction, maintenance and rewarming (Figure 1), each
phase produces several changes in normal physiology. Clini-
cians should be aware of phase events and inter individual
differences. Hypothermia induction should be started as
soon as possible to minimize neurologic damage. Infusing
cold fluids, e.g., Ringer’s lactate >25 ml/kg at 4°C, is the
easiest and most effective method for inducing hypothermia
[12]. During hypothermia, the patient’s central temperature
should be closely monitored. The preferred probe locations
are brain or core temperature, such as central venous,
esophageal, tympanic, nasopharyngeal, bladder and rectum
sites. This order represents the grade of correlation with
brain temperature [13-15].
Hypothermia is not exempt from complications (Figure 1).
Major hypothermia-related complications include cardiac
arrhythmias, coagulopathy, hypokalemia, and infections, ofFigure 1 Physiological changes during hypothermia. Severe specific event
scale in hours is for illustrative purposes only.which pneumonia is the most frequently reported [16,17].
Other reported minor complications are thrombocytopenia,
hyperamylasemia, prolonged PR and QT intervals and
sinus bradycardia, which are generally not associated with
important clinical impact [16]. Currently, these complica-
tions are not common, because most of them develop with
temperatures of 32°C and current protocols use target tem-
peratures of 33–34°C. Lower temperature levels have not
demonstrated benefits [18]. Internal cooling methods are
associated with vascular complications, such as catheter-
related infections, deep venous thrombosis and vascular
dissection. Fortunately, these types of complications occur
in <4% of cases [9,19].
A key adverse effect of hypothermia is shivering, which
may cause great discomfort to the patient, triggering
massive increases in systemic and cerebral energy con-
sumption, that produce considerably slower cooling rates
and increase intracranial pressure (ICP) [20-22]. Previously,
the use of profound sedation and neuromuscular blockades
were the only methods to avoid shivering. However, two
studies have demonstrated that it is possible to maintain
mild hypothermia with conscious patients using a combin-
ation of non-pharmacologic approaches, such as external
warming (available for internal cooling methods) and low
doses of meperidine and buspirone [23,24].s may occur during the three phases of hypothermia procedure. Time
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Ischemic injury: stroke and cardiac arrest
Currently, stroke is a prevalent cause of morbimortality
worldwide. Death and severe functional impairment
rates remain high, because of the low likelihood of
timely thrombolysis treatment. Nearly 70% of acute
stroke patients arrive in the emergency room at a time
that exceeds the therapeutic window for using thromb-
olysis. The door-to-needle times account for another
percentage of these high rates [25]. Finally, fewer than
5% of the candidate patients receive thrombolysis [26].
Numerous studies of stroke in animal models have evalu-
ated the benefits of therapeutic hypothermia. Some of them
have demonstrated the efficacy of therapeutic hypothermia
before or during experimental brain ischemia; however,
they lack clinical applicability because these scenarios do
not represent real life (Table 1). One meta-analysis of these
data concluded that hypothermia reduced approximately
44% of the infarction size and improved the neurological
outcome; moderate hypothermia was required to obtain
this benefit, although it could also be achieved with mild
hypothermia. A shorter elapsed time from injury to
hypothermia resulted in a smaller infarction size [27].
Protective mechanisms underlying hypothermia are re-
lated to the reduction of energy consumption by blocking
intracellular signaling events, such as calcium movements
that prevent ATP depletion and free radical production.
Moreover, hypothermia modulates the inflammatory and
apoptotic signaling pathways, favoring trophic and anti-
apoptotic protein synthesis [28], resulting in a reduction of
excitatory neurotransmitters and inflammatory response
[29].
Since 2002, when the trial “Hypothermia after Cardiac
Arrest Study Group” demonstrated the clinical benefits of
therapeutic hypothermia for improving neurological and
mortality outcomes in patients suffering TV/FV cardiacTable 1 Summary of therapeutic hypothermia; indications, pe
Clinical Scenario Efficacy Evidence





Increased ICP Effective RCTs and cohort studies
Cardiac arrest (PEA or asystole) Possible Case series
Hypoxic encephalopathy in hanging
injury cases
Feasible Case series
Ischemic Stroke Feasible Small RCTs, ongoing trials
Intracerebral hemorrhage Unknown Case series
Subarachnoid hemorrhage Unknown Case series
Traumatic brain injury Unknown RCTs with conflicting resea
findings, ongoing trialsarrest [3], many studies have shown the positive effects of
hypothermia on neuronal protection in global brain ische-
mia [2,30,31]. However, the evidence of therapeutic
hypothermia for focal cerebral ischemia in strokes remains
inconclusive. The disparity in the outcomes may be attrib-
uted to the pathophysiological mechanism differences:
cardiac arrest is associated with global hypoperfusion,
whereas ischemic stroke entails an abrupt and focal inter-
ruption of brain circulation, generating an irreversible in-
farction zone and a peripheral ischemic zone (penumbra),
which is capable of recovery. It is important to consider
that the neuronal death-associated mechanism in focal
cerebral ischemia, primarily occurs through anoxic - is-
chemic cell death, whereas in global hypoperfusion, there
is an injury cascade (such as glutamate excitotoxicity, cal-
cium intracellular intoxication and free-radical injury) that
evolves secondary to molecular cell death [32]. Because
hypothermia has been demonstrated to play a key role in
preventing reperfusion injury, this phenomenon is less im-
portant in the focal setting of stroke [32,33]. Indeed, an-
other recognized indication for hypothermia is neonatal
encephalopathy, which is a model of global brain ischemia,
similar to cardiac arrest, and there is substantial evidence
that this treatment reduces the risk of death or disability in
infants [34,35].
Whereas nearly every study of therapeutic hypothermia
in strokes assumes previous use of thrombolysis, only a
few trials have directly studied the safety of using a
combination of both therapies [6]. From them, we
highlighted the ICTuS-L trial (Intravenous Thrombolysis
plus Hypothermia for Acute Treatment of Ischemic Stroke).
Unfortunately, this study included a small number of pa-
tients (n=59) and was underpowered to demonstrate a sig-
nificant benefit in the treated group. However, this trial
established the feasibility and safety of using both therapies.
An increased rate of complications was not reported [36].rformance, type of evidence and proposed protocols
Protocol
ohort Temperature target 32-34°C for 12–24 h [2,3,30,31]
Moderate or severe HIE, should be treated within 6 h of
delivery to 32–34°C for 72 h, at slow rewarming rate [34,35]
32–36°C (tailored according ICP level) [17,64,65,68]
Target temperature 32–34°C for 12–24 h [9,10,12,69]
Target temperature 32–34°C > 48 h [70,71]




rch Target temperature 32–34°C for > 48 h [59-63]
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therapy in patients who are considered to be unsuitable
for thrombolysis. Schwab et al. showed that hypothermia
played a key role in the prevention of brain edema after
the thrombolytic window period in hemispheric infarcts.
Another study highlighted the importance of a slow
rewarming phase to avoid a rebound effect of ICP [37,38].
Moreover, the combination of hypothermia and hemicra-
niectomy in massive strokes has been tested in small pro-
spective studies. Only, a slight but not statistically
significant benefit was demonstrated in terms of neuro-
logical outcomes [39].
Hemorrhagic injury: stroke
Spontaneous hemorrhagic stroke is associated with
greater mortality than is ischemic stroke. There is no
specific therapy with proven benefits for hemorrhagic
stroke, which can reach a 30-day mortality rate of up to
52% [40]. The prognostic factors for hemorrhagic stroke
are the initial size of the hematoma, re-bleeding events,
hematoma expansion and peri-hemorrhagic edema
[41-43]. Also, an elevated serum glucose measurement at
the time of admission is a strong and less well-known poor
prognostic factor [44]. It is a stress response marker and is
associated with a larger hematoma size, cell death,
hematoma expansion and peri-hemorrhagic edema [44,45].
In cases of intraparenchymal hemorrhage, few studies
have used hypothermia, showing that hypothermia can re-
duce the disruption of the blood–brain barrier and peri-
hematoma edema. However, these findings have not been
correlated with improved neurological outcomes [46,47].
Furthermore, it has been shown that hypothermia during
hemorrhagic stroke is not associated with a reduction in
the size of the original lesion [47]. Only a small clinical
study has suggested that hypothermia has the positive ef-
fect of reducing the extent of edema during the first seven
days; this effect is not lost with rewarming [48].
A Cochrane review published in 2009, which included
eight clinical trials (six randomized and two controlled,
n=423) concluded that there is not a significant positive
effect of hypothermia in the management of ischemic
and hemorrhagic stroke [49].
Hemorrhagic injury: SAH
Hyperthermia worsens the neurological evolution of pa-
tients suffering ischemic or hemorrhagic stroke. Among
hemorrhagic strokes, SAH represents a particular sce-
nario for the usefulness of TTM. These patients exhibit
a high rate of hyperthermia, as much as 70% during the
first 10 days, been the intraventricular hemorrhage one
of the primary risk factors [50].
The use of hypothermia in SAH goes back as far as 1954,
when it was used as a neuroprotective measure against
bleeding or ischemia during aneurysm repair surgery [51].Badjatia et al. studied the effects of temperature control
and neurologic outcomes in SAH. They demonstrated a
reduced risk of poor neurologic outcome 12 months
after SAH; however, it should be noted that the studied
intervention was the aggressive management of fever
versus conventional fever control and not formal
hypothermia [52].
The “Intraoperative Hypothermia for Aneurysm Surgery
Trial” studied the impact of hypothermia during acute
aneurysmal SAH clipping procedures. This multicenter
randomized clinical trial (n=1001) demonstrated that
hypothermia was associated with more frequent bacteremia
episodes, without clinical benefit. This result could be ex-
plained because of the good previous clinical condition in
both study arms and the absence of an important acute
brain injury in the selected patients [53].
Traumatic injury: TBI
Traumatic brain injury is the primary cause of world-
wide morbimortality in young people (<45 years old)
[54]. The annual incidence of TBI in the USA has been
estimated to be 1.4 million cases, with 50,000 related
deaths [55], whereas in Europe, there is a similar land-
scape [56]. Today, a specific treatment remains lacking.
Notably, cell damage is not only produced by the
trauma itself, but by a series of pathophysiological mecha-
nisms, which increase and perpetuate the damage caused
by the initial insult. The mechanisms of this secondary
damage are cerebral ischemia and hypoxia, excitotoxicity,
inflammation, oxidative stress, metabolic dysfunction, sei-
zures, brain edema and ICP elevation, namely, intracra-
nial hypertension (IH), through diminished brain
perfusion pressure. IH is one of major determinant of
outcome [57,58].
Evolution of secondary damage mechanisms has been
studied in the experimental setting, and can be divided
into three distinct phases: acute, sub-acute and chronic.
Varying from acute mechanism such as excitotoxicity,
intracellular enzyme activation, free radical production
and ischemia to subacute inflammation and chronic
gliosis formation. This evolution supports an important
point: neuroprotective treatments for TBI should be ex-
tended up to 72 h.
Marion et al. in a 1997 published a randomized study
involving 84 patients with severe TBI who were treated
using mild hypothermia (33°C for 24 h). There was a sig-
nificantly better neurologic recovery at 3 months and at
6 months among the patients with GCS scores of 5–7 at
the time of admission to the hospital [59]. At the time of
this review, not a single therapy for patients with TBI
had demonstrated such powerful neuroprotective effi-
cacy. Subsequent clinical studies have initiated late
hypothermia in the course of TBI. Clifton et al. pub-
lished two of the largest series of patients with severe
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NABIS: H I & II), who were randomized to early
hypothermia (2–5 h) versus normothermia. Both studies
showed that therapeutic hypothermia had no impact on
the neurologic results [60,61].
Jiang et al. revisited the time-dependent effect of
hypothermia for TBI. In 2006 published a randomized
study of 215 patients with severe TBI, which showed
that prolonged hypothermia (5 ± 1.3 days) was more
effective than conventional hypothermia (2 ± 0.6 days)
in reducing the number of patients with poor neuro-
logical outcomes. Both patients arms where cooling to
reach 33–35°C of rectal temperature, using cooling
blankets [62].
Kramer et al. in a 2009 Cochrane review, included 23
trials and 1,614 patients with the following criteria: early
hypothermia, target temperatures of 35°C for at least 12 h
and the need for hospitalization. Authors concluded that
those patients treated with hypothermia had better results
in terms of mortality and neurologic outcomes. However,
this association was statistically significant only in studies
with poor methodological quality [63].
To prevent ongoing brain edema and refractory IH
management, the use of hypothermia in the sub-acute
phase has been widely studied. In 2003, Tokutomi
et al. presented a series of 31 high-risk patients who
were hospitalized for severe TBI with GCS scores of
≤5 at the time of admission to the hospital. Almost,
74% of the patients required surgical management. In
addition to show the benefit of the use of hypothermia
for treating IH, Tokutomi et al. described an optimal
coupling between blood flow and brain metabolism at
35°C, with no compromise in perfusion pressure [64].
The same authors published another trial, using 35°C
and compared the results with patients who were
previously treated at temperatures of 33°C; the post
hoc analysis demonstrated better control of brain per-
fusion pressure at 35°C without differences in ICP
levels, complications, mortality or neurological out-
comes [65].
In April 2010, the European Society of Intensive Care
Medicine started a multicenter randomized clinical trial
with the aim of recruiting 1,800 TBI patients to evaluate
the benefits of therapeutic hypothermia (32–35°C) in
ICP control, morbidity and six-month mortality [66].
Interestingly, this study did not establish common cri-
teria for the duration of hypothermia; however, it was
suggested prolonging hypothermia as long as necessary
to maintain an ICP of <20 mmHg.
Finally, a systematic review in 2012 collected 13 ran-
domized clinical trials and 5 observational studies con-
cerning IH management in patients with TBI using
therapeutic hypothermia. A significant reduction of ICP
was evident in all of the patients [17].Our experience
In the last decade, our group was inspired by the lack of
neuroprotective treatments and by the use of hypothermia
after TV/FV cardiac arrest to explore the effectiveness of
hypothermia in other clinical settings, such as cardiac ar-
rest due to non-shockable rhythms, acute liver failure with
brain edema, refractory intracranial hypertension (rIH) or
full neuroprotection intended for acute brain injuries. The
medical management of rIH is complex because of the as-
sociated unfavorable clinical outcomes [57] and toxic
treatment alternatives, such as barbiturate coma [67].
Additional challenges arise from the prolonged nature of
IH, which can continue for approximately one week inde-
pendent of the nature of the acute brain injury. Debate ex-
ists concerning the optimal strategies for treating these
patients. We studied the performance and outcomes of
patients who received therapeutic hypothermia in the last
five years.
We defined rIH without surgically correctible causes
as ICP >20 mmHg for over one hour, despite a manage-
ment protocol using the first and second tiers of treat-
ment. We included in a common database all patients
who were admitted to our intensive care to undergo
therapeutic hypothermia from 2008. For referral reasons,
we did not receive patients who were in cardiac arrest
due to shockable rhythms. Hypothermia was performed
using endovascular cooling (Alsius, Zoll, Chelmsford,
MA, USA) with a target temperature of 33°C. Data are
expressed as median and interquartile range [IQR].
To date, we have included 30 patients with an average
age of 28 years [24–40; IQR], 53% male, and an average
APACHE II score of 16 [12–18; IQR]. Of these, 25% of
the patients were referred for hypothermia after cardiac
arrest, 50% were referred for rIH, and 25% were referred
for full neuroprotective intent. The etiology of refractory
intracranial hypertension was diverse, including acute
brain injury (TBI, malignant stroke, SAH, and post-
neurosurgical edema) and liver failure. In patients with
rIH, the ICP levels were 23 mmHg [19–24; IQR] before
hypothermia versus 13 mmHg [10.3–24; IQR] during
hypothermia (p=0.003). Mortality was 36% in this co-
hort, and the mean Glasgow Outcome Score-Extended
(GOS-E) at three months was 5 [3–7; IQR] in the survi-
vors. Cardiac arrest survivors, not VT/FV patients, had
poor outcomes with a mean GOS-E of 4 at three months.
Notably, the surviving patients with rIH had a lower per-
centage of time with ICP >20 mmHg during the entire
course of hypothermia: 3.3% [0.6–7; IQR] versus 27.2%
[19.8–44.9; IQR] (p < 0.01). The complications related to
hypothermia did not exceed two per patient, and none re-
quired withdrawal of the hypothermia procedure.
Thus, in our experience, hypothermia exhibited mod-
est performance after cardiac arrest of non- shockable
rhythms. However, hypothermia was an effective and
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thus helping to produce good neurological outcomes in
survivors.
Conclusions
Hypothermia has evolved as the strongest neuroprotec-
tive intervention in clinical therapy. Currently, treatment
with hypothermia is standard medical care after VT/VF
cardiac arrest-related coma, and neonatal encephalop-
athy. Its utility, in addition to treatment for cardiac ar-
rest, is noted in the course of acute brain injuries.
However, from our perspective, hypothermia can be
used with a reasonable likelihood of success when IH
complicates any brain injury, such as stroke or traumatic
brain injury, because IH diminishes the brain blood
pressure, generating a condition recognized as global
brain hypoperfusion. In this situation, the pathophysio-
logical mechanisms of brain injury are susceptible to
treatment with hypothermia. The primary objective of
hypothermia is to preserve the central nervous system
tissue while making time to resolve the original path-
ology. Although, this recommendation represents only
the beginning of TTR because there are many details
that remain to be elucidated, such as the exact time win-
dow for each pathology, the time of treatment, the target
temperature, rewarming protocols, adequate therapeutic
markers and what therapies in combination with
hypothermia would offer better neuroprotection.
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